Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 719 in Rheumatoid Arthritis
NCT00038298Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2002
- Primary completion
- May 2004
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, randomised, double-blind trial of AGM-719 in rheumatoid arthritis (RA) (4 arms), sponsored by Amgen. Primary endpoint: Favorable safety profile in subjects with RA receiving methotrexate at 24 weeks. Started Apr 2002; status: completed.
02
Drugs
AGM-719
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00038298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038298.